文献速递泌尿生殖与妇科肿瘤放疗

基于活检标本的基因组分类器在高危前列腺癌中的分析:NRG肿瘤学/放射治疗肿瘤学组9202、9413和9902三项3期随机试验的荟萃分析

Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-12-31

本研究在高危前列腺癌根治性放疗前的活检标本中验证Decipher基因组分类器(GC)的预后价值,汇总NRG/RTOG 9202、9413和9902三项3期随机试验中265例通过质控的样本,中位随访11年。GC评分与远处转移、前列腺癌特异性死亡和总生存独立相关,且在不同雄激素剥夺治疗时长患者中预后能力相似。

要点

  • GC评分每增加0.1单位,远处转移、前列腺癌特异性死亡和总生存的多变量风险比均独立升高。
  • GC在短程和长程雄激素剥夺治疗患者中预后能力相似,但绝对获益因GC风险而异。
  • 这是首次在前瞻性随机试验的放疗前前列腺癌活检标本中验证基因表达生物标志物。

核心结论

  • 这是首次在前瞻性随机试验的放疗前前列腺癌活检标本中验证基因表达生物标志物,证明GC评分与远处转移、前列腺癌特异性死亡和总生存独立相关。
  • 高危前列腺癌是异质性疾病状态,GC可改善风险分层以帮助个体化共享决策。

研究设计与样本

  • 预先设定的分析计划(NRG-GU-TS006)获准从NRG生物样本库获取NRG/RTOG 9202、9413和9902三项3期随机试验入组患者的活检标本石蜡组织。
  • 经中心复核后,对最高级别肿瘤在临床级全转录组芯片上进行检测并获得GC评分。
  • 主要目标为验证GC对远处转移的独立预后能力,次要目标为前列腺癌特异性死亡和总生存,采用Cox单变量和多变量分析。

主要发现

  • 共获得385例样本的GC评分,其中265例通过芯片质量控制(69%),中位随访11年(四分位距9-13年)。
  • 汇总队列单变量分析中,GC每0.1单位与远处转移(sHR 1.29,95%CI 1.18-1.41,P<.001)、前列腺癌特异性死亡(sHR 1.28,95%CI 1.16-1.41,P<.001)和总生存(HR 1.16,95%CI 1.08-1.22,P<.001)相关。
  • 多变量分析中,调整年龄、前列腺特异性抗原、Gleason评分、cT分期、试验和随机治疗组后,GC每0.1单位与远处转移(sHR 1.22,95%CI 1.09-1.36)、前列腺癌特异性死亡(sHR 1.23,95%CI 1.09-1.39)和总生存(HR 1.12,95%CI 1.05-1.20)独立相关。
  • GC在接受短程或长程雄激素剥夺治疗的患者中预后能力相似,但绝对结局改善因GC风险而异。

关键数值与推荐

  • GC评分每0.1单位单变量远处转移sHR 1.29(95%CI 1.18-1.41,P<.001),多变量sHR 1.22(95%CI 1.09-1.36)。
  • GC评分每0.1单位单变量前列腺癌特异性死亡sHR 1.28(95%CI 1.16-1.41,P<.001),多变量sHR 1.23(95%CI 1.09-1.39)。
  • GC评分每0.1单位单变量总生存HR 1.16(95%CI 1.08-1.22,P<.001),多变量HR 1.12(95%CI 1.05-1.20)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Decipher is a genomic classifier (GC) prospectively validated postprostatectomy. We validated the performance of the GC in pretreatment biopsy samples within the context of 3 randomized phase 3 high-risk definitive radiation therapy trials. METHODS AND MATERIALS: A prespecified analysis plan (NRG-GU-TS006) was approved to obtain formalin-fixed paraffin-embedded tissue from biopsy specimens from the NRG biobank from patients enrolled in the NRG/Radiation Therapy Oncology Group (RTOG) 9202, 9413, and 9902 phase 3 randomized trials. After central review, the highest-grade tumors were profiled on clinical-grade whole-transcriptome arrays and GC scores were obtained. The primary objective was to validate the independent prognostic ability for the GC for distant metastases (DM), and secondary for prostate cancer-specific mortality (PCSM) and overall survival (OS) with Cox univariable and multivariable analyses. RESULTS: GC scores were obtained on 385 samples, of which 265 passed microarray quality control (69%) and had a median follow-up of 11 years (interquartile range, 9-13). In the pooled cohort, on univariable analysis, the GC was shown to be a prognostic factor for DM (per 0.1 unit; subdistribution hazard ratio [sHR], 1.29; 95% confidence interval [CI], 1.18-1.41; P < .001), PCSM (sHR, 1.28; 95% CI, 1.16-1.41; P < .001), and OS (hazard ratio [HR], 1.16; 95% CI, 1.08-1.22; P < .001). On multivariable analyses, the GC (per 0.1 unit) was independently associated with DM (sHR, 1.22; 95% CI, 1.09-1.36), PCSM (sHR, 1.23; 95% CI, 1.09-1.39), and OS (HR, 1.12; 95% CI, 1.05-1.20) after adjusting for age, Prostate Specific Antigen, Gleason score, cT stage, trial, and randomized treatment arm. GC had similar prognostic ability in patients receiving short-term or long-term androgen-deprivation therapy, but the absolute improvement in outcome varied by GC risk. CONCLUSIONS: This is the first validation of a gene expression biomarker on pretreatment prostate cancer biopsy samples from prospective randomized trials and demonstrates an independent association of GC score with DM, PCSM, and OS. High-risk prostate cancer is a heterogeneous disease state, and GC can improve risk stratification to help personalize shared decision making.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nguyen PL, Huang HR, Spratt DE, et al. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys. 2022. PMID: 36596347. doi:10.1016/j.ijrobp.2022.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。